Stockscreener 앱 받기
166.23
2.97%
4.79
시간 외 거래:
166.39
0.16
+0.10%
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Best Momentum Stocks to Buy for June 24th - Yahoo Finance Singapore
Neurocrine Biosciences Inc (NBIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
New Strong Buy Stocks for June 24th - Yahoo Finance Singapore
Best Value Stocks to Buy for June 24th - Yahoo Finance Singapore
Neurocrine Biosciences (NBIX) Pe Ratio (TTM) - Zacks Investment Research
Stifel reiterates Neurocrine Bio stock rating on Vykat potential By Investing.com - Investing.com Australia
Stifel reiterates Neurocrine Bio stock rating on Vykat potential - Investing.com
What Neurocrine Biosciences (NBIX)'s New CRENESSITY CAH Data Means For Shareholders - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A 22.8% Potential Upside Amid Strong Growth Prospects - DirectorsTalk Interviews
Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Decent Value Play with Strong Fundamentals - ChartMill
Neurocrine Biosciences (NBIX) Stock Could Be 18% Undervalued After ENDO 2026 CRENESSITY Data - simplywall.st
Neurocrine Biosciences Inc (NBIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neurocrine Biosciences Inc (NBIX) Institutional Confidence - TradingKey
Neurocrine Biosciences Inc (NBIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NEUROCRINE BIOSCIENCES INC (NBIX) Stock Chart - ChartMill
Neurocrine Biosciences Inc (NBIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurocrine Biosciences Inc (NBIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neurocrine Biosciences Inc (NBIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neurocrine Biosciences Inc (NBIX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $246 - Moomoo
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout Candidate - ChartMill
Neurocrine presents long-term data on Prader-Willi drug By Investing.com - Investing.com South Africa
Neurocrine presents long-term data on Prader-Willi drug - Investing.com
Neurocrine presents case study on Crenessity for rare CAH subtype By Investing.com - Investing.com Australia
Neurocrine presents case study on Crenessity for rare CAH subtype - Investing.com
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period - PR Newswire
Neurocrine Biosciences (NBIX) Presents First Retrospective Case Series of CRENESSITY - StreetInsider
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 - The Grand Junction Daily Sentinel
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now? - Insider Monkey
Neurocrine presents 2-year Crenessity data at ENDO 2026 By Investing.com - Investing.com South Africa
Neurocrine (NBIX) Reports Positive Phase 3 Data on Crenessity - GuruFocus
Neurocrine reports positive 2-year pediatric CAH data - grafa.com
Two-year data bolster Neurocrine’s Crenessity case in pediatric CAH - The Pharma Letter
Neurocrine presents 2-year Crenessity data at ENDO 2026 - Investing.com UK
Neurocrine Biosciences Presents New Two-Year CRENESSITY Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults With Classic Congenital Adrenal Hyperplasia - marketscreener.com
Neurocrine presents two-year pediatric data for Crenessity - Investing.com
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - Quantisnow
Neurocrine presents two-year CRENESSITY data showing growth improvements - StreetInsider
Two-year trial drug tied to taller height in children with CAH - Stock Titan
Neurocrine shows two-year CRENESSITY data at ENDO 2026 medical meeting - StreetInsider
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Investor Outlook Highlights 20.73% Potential Upside - DirectorsTalk Interviews
How New INGREZZA TD Data in Underserved Patients Could Shape Neurocrine Biosciences’ (NBIX) Investment Story - simplywall.st
Marquis Who's Who Honors Noah Post for Expertise in Pharmaceuticals - 24-7 Press Release Newswire
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - simplywall.st
Neurocrine Biosciences (NBIX) beats Q1 earnings and revenue estimates - MSN
INGREZZA Data In Complex Patients Adds Support For Neurocrine Valuation Story - simplywall.st
Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys - Benzinga
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book Strategy - ChartMill
Neurocrine Biosciences(NBIX.US) Director Sells US$4.13 Million in Common Stock - Moomoo
Neurocrine Biosciences director Stephen A. Sherwin sells $4.13m stock - Investing.com UK
Neurocrine Biosciences director Stephen A. Sherwin sells $4.13m stock By Investing.com - Investing.com Canada
1.11%
자본화:
|
볼륨(24시간):